IE
APGE icon

Israel Englander’s Apogee Therapeutics APGE Stock Holding History

Israel Englander’s Portfolio APGE Stock Details APGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-10,000
Closed -$434K – 6000
2025
Q2 		$434K Buy
+10,000
New +$380K ﹤0.01% 4987

Other funds holding APGE

VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $10.2B AUM 67.73% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return

Israel Englander's APGE Position: Q2 2026 in Review

Israel Englander increased its Apogee Therapeutics (APGE) stake by 1,511% in Q2 2026, buying an estimated $126M and bringing the position to 1,491,404 shares worth $198M. The position accounts for 0.07% of the portfolio, ranked #244.

Israel Englander first reported a position in APGE in Q4 2023 and has held it in 11 quarters since. 285 funds tracked by Wall St. Rank hold APGE as of Q2 2026.

  • Israel Englander held 1,491,404 shares of Apogee Therapeutics worth $198M as of Q2 2026.
  • Israel Englander bought 1,398,812 Apogee Therapeutics shares in Q2 2026, an estimated $126M.
  • Apogee Therapeutics made up 0.07% of Israel Englander's portfolio in Q2 2026, its #244 holding.
  • Israel Englander first reported a position in Apogee Therapeutics in Q4 2023 and has held it in 11 quarters since.
  • 285 funds tracked by Wall St. Rank held Apogee Therapeutics as of Q2 2026.

Based on Millennium Management's 13F filing for Q2 2026, filed 14 Aug 2026.